Immunotherapy with antibodies directed against programmed death (PD-1) or programmed death-ligand 1, PD-L1 (nivolumab and pembrolizumab, respectively) have been approved by the FDA in 2017 for the treatment of immunogenic deficient mismatch repair or high levels of microsatellite instability tumors, including CRC [68,69], and should continue to be investigated. Here, CD274 is linked to colorectal carcinoma.